North America Diabetes Drugs Market Growth, Trends and Forecasts 2017 - 2022

  • ID: 4388037
  • Report
  • Region: North America, United States
  • 120 pages
  • Mordor Intelligence
1 of 4
Diabetes, often referred to by doctors as diabetes mellitus, describes a group of metabolic diseases in which the person has high blood glucose (blood sugar), either because insulin production is inadequate, or because the body's cells do not respond properly to insulin, or both. Patients with high blood sugar will typically experience polyuria (frequent urination), they will become increasingly thirsty (polydipsia) and hungry (polyphagia). Diabetes is a chronic metabolic disease wherein the body is either not able to produce insulin (type-1) or is not able to utilize the generated insulin (type-2). This elevated sugar level leads to various symptoms such as increased thirst, weight loss, high appetite, frequent and sweet smelled urination. If untreated, diabetes causes various acute and chronic life-threatening complications. This report studies the current as well as future scenario of the diabetes diagnostic devices and drugs market globally.

The Global diabetes drugs market valued as a $10.65 billion market in 2014 is expected to grow at an exponential rate and is expected to become a $15.37 billion by 2019 at a CAGR of about 7.61%. This market is growing at a very high rate.

The market is basically segmented into two categories namely on the basis of diabetic drugs and on the basis of geography. The diabetic drugs market is again segmented into categories which are insulin derivatives and oral diabetic medication drugs. On the basis of geography the market is segmented into categories which are North America, Europe, APAC and the Rest of the World.

The North American Diabetes Drugsmarket holds the major share in the world market scenario. The market is valued at $16 billion in 2010 and is expected to reach $28 billion by the end of 2017 with a CAGR of 8.3%.

The major drivers for this market growth are rise in the number of diabetics, complexities in alternative diabetic therapies and strong encouragement from the Governments. The major challenges faced by this market are regulatory framework issues, lack of awareness among people and cost sensitivity issues.

The major players in this market are Abbott Labs, Merck & Co, Dexcom Inc, Johnson & Johnson.
READ MORE
Note: Product cover images may vary from those shown
2 of 4
1.INTRODUCTION
1.1 Report Description
1.2 Research Methodology
1.3 Stakeholders
2. EXECUTIVE SUMMARY
2.1 Key Findings
2.2 Market Overview
3. MARKET OVERVIEW
3.1 Market Defenition
3.1.1 Introduction
3.2 Market Segmentation
3.2.1 Drugs
3.2.2 Geography
3.3 Market Drivers
3.3.1 Rise in number of diabetics
3.3.2 Complexities in alternative diabetes therapy
3.3.3 Government Initiatives
3.4 Market Challenges
3.4.1 Effective Disease Management
3.4.2 Regulatory Framework
3.4.3 Low awareness
3.4.4 Cost sensitivity
4. NORTH AMERICA MARKETS:SEGMENTATION BY DRUGS
4.1 Insulin Derivatives
4.1.1 Rapid acting insulin
4.1.2 Intermediate acting insulin
4.1.3 Long acting insulin
4.2 Oral Diabetic Medication Drugs
4.2.1 Sulfonyulrea
4.2.2 Metformin
4.2.3 Alpha-Glucosidace inhibitor
4.2.4 Thiazolidinediones
4.2.5 Biguanide
4.2.6 Meglitinides
4.2.7 GPP4-Inhibitors
5. NORTH AMERICAN MARKETS:SEGMENTATION BY GEOGRAPHY
5.1 USA
5.2 Canada
5.3 Mexico
6. COMPETITIVE LANDSCAPE
6.1 Introduction
6.2 Mergers & Acquisitions
6.3 Expansions
6.4 New Product Launch
6.5 Collaborations
7. COMPANY PROFILES
7.1 Abbott Laboratories
7.2 Dexcom Inc
7.3 Johnson & Johnson
7.4 Merck & Co.
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll